A that also received the usual treatment for CHF, including digitalis, diuretics, and low-sodium diet, etc. 3 In addition, there was a reduction in hospitalization for CHF in the ACE inhibitor group, as well as a reduction s you know, there have not, as yet, been any long-term clinical trials to answer the question regarding benefits of antihypertensive therapy with angiotensin converting enzyme (ACE) inhibitors or calcium channel blockers (CCB). in myocardial infarctions ( MI ) . There are several studies presently underway. There are A minority of patients in these trials were hypertensome data, however, in subsets of patients that demon-sive -2,653 compared to 4,100 who were normotenstrate benefit with the ACE inhibitors and some contro-sive. In the subset of hypertensive subjects, there was versial data regarding the CCB. also a significant reduction in CHF, but other end- Table 1 lists the clinical trials that have shown a point reductions that were statistically significant in benefit for reducing cardiovascular disease in treated the normotensive group failed to reach statistical sighypertensives. A statistically significant reduction in nificance in the hypertensive group; MI, angina, and morbidity and mortality from stroke, coronary artery total mortality were not reduced significantly in the disease, congestive heart failure ( CHF ) , and total car-hypertensive subjects. 4 There were some reductions, diovascular disease has been demonstrated. 1, 2 All of and it is quite possible that a study that included more these trials were diuretic-or b-blocker-based, and hypertensive patients would have yielded significant four compared a diuretic and a b-blocker.
results. When cardiac endpoints were combined the ACE inhibitor-treated group showed a significant de-
RESULTS OF ACE INHIBITOR THERAPY IN
crease ( P õ .003 ) compared to placebo ( Figure 1 ) .
PATIENT SUBSETS
The Survival and Ventricular Enlargement ( SAVE ) The use of ACE inhibitors has clearly improved the trial studied patients who had suffered a myocardial outlook for patients with CHF due to systolic dysfunc-infarction and had ejection fractions õ 40% in the tion and for patients with type I diabetic nephropathy. postinfarction period. Some had symptomatic heart In the Studies of Left Ventricular Dysfunction ( SOLVD ) failure, some did not. Captopril was the ACE inhibitor trial, patients with CHF, symptomatic or asymptomatic, that was used in this placebo-controlled trial. Signifiwith ejection fractions õ 35% who received an ACE cant risk reductions for death from cardiovascular inhibitor ( enalapril ) in additional to a diuretic and digi-causes, for recurrent MI, and for death from CHF were talis experienced a statistically significant reduction ( P noted in the ACE inhibitor group. õ .0036 ) in mortality, compared to the placebo group Whether or not systolic dysfunction occurred after a myocardial infarction or whether it occurred for other reasons, the use of an ACE inhibitor ( in addition to a diuretic or digitalis in most instances ) has been shown of renal function with possible acute renal failure, and the danger of producing hyperkalemia. Patients must be carefully monitored. strated that the benefits in terms of reduction in total It is probably prudent not to give an ACE inhibitor mortality were dependent upon the pretreatment ejec-to patients who have serum creatinine levels of ú3 mg/ tion fraction ( EF ) . 6 In patients with EF õ 25% there dL. Although there are no data on long-term benefits was a significant reduction in total mortality of about with ACE inhibitors in most hypertensive subjects, 31%, but this trend did not apply to subjects with EF there is evidence that these agents are useful in treating ú 25%. There was no significant reduction in sudden patients with type I diabetic nephropathy and patients death or mortality from MI.
with systolic dysfunction of the left ventricle. I believe that the ACE inhibitors are beneficial for CALCIUM CHANNEL BLOCKERS hypertensive and normotensive patients with CHF due to systolic dysfunction.
Is there any evidence that calcium antagonists offer specific advantages in the therapy of hypertension?
ACE INHIBITORS AND THE KIDNEY
In 1987 Parving et al reported that in 11 insulin-dependent ( type I ) diabetics who already had some evidence of nephropathy antihypertensive treatment reduced the slope of the decline in glomerular filtration rate ( GFR ) . Before treatment, the GFR was declining at a rate of almost 1 mL /min /month, whereas after antihypertensive treatment was initiated, blood pressure was reduced and the GFR decline retarded to as little as 0.1 mL /min /month, and proteinuria also diminished . 7 Although this study included only 11 patients, they were insulin-dependent diabetics with advancing renal failure due to diabetic nephropathy. The medications used in these studies were metoprolol, hydralazine, methyldopa, a diuretic, and guanethidine.
The question is whether or not any of the newer FIGURE 1. during their acute MI and who received diltiazem did better than the placebo group. When the non-CHF and the CHF groups were combined, there was no statistically significant reduction in post-MI events. Yusuf et al 11 reviewed the effect of verapamil and diltiazem on mortality following MI. There were no statistically significant benefits from the use of these agents. In the same analysis reinfarction rates were reduced 20% to 22%, but this was not statistically significant. These studies used short-acting formulations of these agents. The results with dihydropyridines, at least the short-acting ones, after an MI are quite negative. A metaanalysis of these suggests that the case control studies are of concern. In one large study, low, medium, and high doses of a b-blocker were compared to low, medium, and high doses of shortAgain, there are no long-term studies, so we must acting CCB on the occurrence of MI in treated hyperexamine some subsets of patients and then, if possible, tensives. 13 The higher the dose of the b-blocker, the speculate on possible benefits. more protection against MI; whereas as the dose of Numerous studies have been done in an attempt to the CCB increased, there was an increase in the risk of established whether or not the CCB are protective MI ( Figure 2 ) . The increase in MI achieved statistical after a myocardial infarction. It has been well estabsignificance for a high dose of short-acting calcium lished that b-blockers reduce morbidity and mortality antagonists, primarily nifedipine. Risk was also inin patients with a previous MI, 9 but the data on calcreased for subjects taking a CCB when compared to cium channel blockers are equivocal or negative. In those taking a diuretic. one study, diltiazem was given soon after an acute
In another study, elderly hypertensive subjects who MI and continued for a period of 2 to 3 years. 10 Overwere taking various short-acting calcium antagonists all, this treatment did not have a significant effect on ( verapamil, diltiazem, and nifedipine ) experienced an recurrent cardiac events, specifically recurrent MI or increase in the risk of CHF compared to those taking heart failure, when compared to placebo, but there a b-blocker or an ACE inhibitor ( Figure 3 ) . 14 There were subgroup differences. Patients who had some are other studies with short-acting CCB that suggest clinical evidence of pulmonary congestion during an increase in ischemic heart disease events and no their acute infarction were actually worse off, in terms significant benefit with regard to retarding the process of recurrent cardiac events, when they were given dilof atherogenesis. 15, 16 tiazem compared to the placebo group. However, those subjects who had no evidence of heart failure Recent reports suggesting that the calcium antago- 
